Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Witjaksono, J.
Right arrow Articles by Rogers, P. A. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Witjaksono, J.
Right arrow Articles by Rogers, P. A. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. suppl_2, pp. 109-114, 1996
© 1996 European Society of Human Reproduction and Embryology

Oestrogen treatment for increased bleeding in Norplant users: preliminary results

Julianto Witjaksono1,4, Tseng M. Lau3, Biran Affandi2 and Peter A. W. Rogers3

1 Department of Obstetrics and Gynaecology, Reproductive Endocrinology Division, Faculty of Medicine, University of Indonesia Jalan Salemba Raya 6 2 Department of Obstetrics and Gynaecology, Klinik Raden Saleh, Faculty of Medicine, University of Indonesia Jalan Raden Saleh 49, Jakarta 10430, Indonesia 3 Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre 246 Clayton Road, Clayton, Victoria 3168, Australia

Correspondence: 4To whom correspondence should be addressed

A clinical study was conducted to assess the effects of oestrogen in controlling increased endometrial bleeding problems in the first year of Norplant® use. Three treatment groups were studied: (i) 50 µg ethinyl oestradiol (EE); (ii) a combined pill containing 30 µg EE and 150 µg levonorgestrel (LNG); and (iii) placebo. Based on menstrual diary records, women with prolonged, frequent or irregular bleeding, as defined by World Health Organization criteria, were randomly allocated to one treatment for 21 days. A first endometrial biopsy was taken before commencing treatment and a second biopsy at either day 14 or 21 of treatment Following treatment, all subjects kept a menstrual diary card for 90 days. In this preliminary study, 48 subjects had completed the full 90 day post-treatment record. Within 21 days of EE treatment, the number of bleeding/spotting days was reduced significantly (P < 0.02). In the 90 days following treatment, the administration of EE and EE+LNG significantly decreased the number of bleeding/spotting days (P < 0.05). There was no reduction in the number of bleeding/spotting episodes in the EE and EE+LNG groups, but the length of each bleeding/spotting episode was significantly shorter (P < 0.05). Histopathological findings of endometrium on day 0 revealed consistent progestogenic effects, and there was no apparent change in response by day 14 or 21 of EE or EE+LNG treatment The results of this study confirm the clinical effectiveness of EE and EE+LNG for the treatment of irregular, frequent and prolonged bleeding in Norplant users.

Key words: breakthrough bleeding/endometrium/ethinyl oestradiol/levonorgestrel/Norplant


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.